Infertility Drugs Market to Grow at 6.2% CAGR Through 2032: Key Drivers and Challenges
The global infertility drugs market is expected to witness substantial growth, with the market size projected to increase from USD 3,589.97 million in 2022 to USD 6,453.7 million by 2032, reflecting a CAGR of 6.2% during the forecast period. This growth can be attributed to several factors, including the rising prevalence of infertility, advancements in medical technologies, and increasing awareness about fertility treatments.
Key growth drivers for the market include the increasing incidence of infertility due to lifestyle changes, delayed pregnancies, environmental factors, and medical conditions such as polycystic ovary syndrome (PCOS) and endometriosis. According to the World Health Organization, around 17.5% of the adult population globally experiences infertility, highlighting the urgent need for accessible and high-quality fertility care.
Recent developments in the market have been marked by significant research and clinical trials aimed at improving the efficacy of infertility drugs. For instance, phase 3 clinical trials have been initiated to evaluate new formulations of gonadotropins, which dominate the market due to their high efficacy in treating infertility. These advancements are expected to drive market growth further.
However, the market also faces challenges, such as the side effects and risks associated with infertility drugs. Common adverse effects include headaches, mood swings, and more severe complications like ovarian hyperstimulation syndrome (OHSS). Additionally, the high cost of treatment and the availability of alternative treatments, such as in-vitro fertilization (IVF), may impact the market’s growth trajectory.
Regionally, North America leads the market due to the rapid uptake of infertility drugs and extensive research activities. The region’s dominance is supported by favorable government initiatives and a well-established healthcare infrastructure. Asia-Pacific is also expected to witness significant growth, driven by increasing awareness and the approval of new infertility treatments in countries like Japan and China.
The global infertility drugs market is poised for steady growth, driven by technological advancements and increasing infertility rates, it must navigate challenges related to drug side effects and high treatment costs to achieve its full potential.
Key Takeaways
- Market Growth: The infertility drugs market is anticipated to grow at a 6.2% CAGR, reaching USD 6,453.7 million by 2032.
- Gonadotropins Dominance: Gonadotropins lead the market with an 8.2% projected CAGR, attributed to their high effectiveness.
- Aromatase Inhibitors Rise: Aromatase inhibitors are expected to grow at a 7.4% CAGR in 2022, driven by high success rates.
- Hospital Pharmacies Lead: Hospital pharmacies dominate with a 53.4% market share and an 8.9% CAGR.
- Online Pharmacies Growing: Other pharmacies, including online, see a 7.2% CAGR and hold a 37.6% market share.
- Women’s Majority: Women constitute 74.6% of the market, with an 8.3% CAGR in 2022.
- Fastest Growing Segment: The women’s segment is the fastest-growing, with a projected 2022-2031 CAGR.
- Infertility Prevalence: Infertility impacts 48 million couples and 186 million individuals worldwide.
- North America Leading: North America leads with a 37.8% market share and a 7.2% CAGR.
- APAC Growth: The Asia Pacific region is the fastest-growing, with a 6.8% CAGR.
Get Sample PDF Report: https://market.us/report/infertility-drugs-market/request-sample/
Infertility Drugs Market Key Segments
Based on Drug Class
- Gonadotropins
- Aromatase Inhibitors
- Selective Estrogen Receptor Modulators (SERMs)
- Dopamine Agonists
- Other Class
Based on Distribution Channel
- Hospital Pharmacy
- Speciality & Retail Pharmacy
- Other Distribution Channels
By End-User
- Men
- Women
Key Regions
- North America (The US, Canada, Mexico)
- Western Europe (Germany, France, The UK, Spain, Italy, Portugal, Ireland, Austria, Switzerland, Benelux, Nordic, Rest of Western Europe)
- Eastern Europe (Russia, Poland, The Czech Republic, Greece, Rest of Eastern Europe)
- APAC (China, Japan, South Korea, India, Australia & New Zealand, Indonesia, Malaysia, Philippines, Singapore, Thailand, Vietnam, Rest of APAC)
- Latin America (Brazil, Colombia, Chile, Argentina, Costa Rica, Rest of Latin America)
- Middle East & Africa (Algeria, Egypt, Israel, Kuwait, Nigeria, Saudi Arabia, South Africa, Turkey, United Arab Emirates, Rest of MEA)
Buy Directly: https://market.us/purchase-report/?report_id=14089
Key Players Analysis
Merck & Co. Inc., known as MSD outside the U.S. and Canada, is actively developing infertility treatments, including corifollitropin alfa for Controlled Ovarian Stimulation (COS). This drug is under review by the FDA and could be the first sustained follicular stimulant for fertility treatments. Merck also offers a diverse portfolio of fertility treatments like GONAL-f, Pergoveris, Luveris, and Cetrotide across over 120 countries, supporting various stages of the fertility treatment cycle.
Ferring B.V. is a prominent player in the infertility treatment sector, recognized for its significant contributions to the development and distribution of reproductive medicines and technologies. The company focuses on peptides and biotechnology, offering products across multiple therapeutic areas, including reproductive health. Ferring maintains a strong commitment to innovation and patient-centric solutions in its approach to addressing infertility.
Organon Group specializes in women’s health, including fertility solutions. Their portfolio includes treatments that address various stages of the reproductive process, aiming to enhance patient outcomes in infertility. Organon emphasizes integrated care approaches and collaborates extensively to expand its reach and effectiveness in the fertility domain.
Abbott Laboratories engages in the infertility drugs market through its comprehensive range of health care solutions, including diagnostics, medical devices, nutritionals, and branded generic pharmaceuticals. While Abbott is broadly focused, its commitment to innovation and healthcare improvement extends to addressing the complexities of infertility with advanced medical technologies and diagnostics.
Novartis AG participates in the infertility treatment market by providing innovative medicines that include hormone therapies among other pharmaceutical solutions. Novartis is dedicated to enhancing patients’ lives through extensive research and development, which reflects in their active engagement in developing treatments that address various aspects of infertility.
Infertility Drugs Market Key Players
- Merck & Co. Inc.
- Ferring B.V.
- Organon Group of Companies
- Abbott Laboratories
- Novartis AG
- Bayer AG
- Pfizer Inc.
- Mankind Pharma Ltd.
- Teva Pharmaceutical Industries Ltd.
- Sanofi S.A.
- Other Key Players
Infertility Drugs Market Report Scope >> Market Value (2023): USD 3589.97 Billion || Forecast Revenue (2033): USD 6453.7 Billion || CAGR (2024-2033): 6.2% || Base Year Estimation: 2023 || Historic Period: 2019-2022 || Forecast Period: 2024-2033.
Inquire More about report: https://market.us/report/infertility-drugs-market/#inquiry
About Market.US
Market.US is renowned for its comprehensive market research and analysis, providing customized and syndicated reports to a global clientele. Specializing in a variety of sectors, they offer strategic insights and detailed market forecasts, assisting businesses in making informed decisions. With a focus on innovation and accuracy, Market.US supports clients in over 126 countries, and maintains a strong repeat customer rate, underscoring their commitment to quality and client satisfaction. Their team excels in delivering exceptional research services, ensuring that no detail is overlooked in any target market.
Contact Details
Market.us (Powered By Prudour Pvt. Ltd.)
Contact No: +1 718 618 4351.
Email: inquiry@market.us
Blog: https://medicalmarketreport.com/
View More Trending Reports
Materiovigilance Market on Upward Trajectory Expected to Hit USD 162.4 Billion by 2033
Adalimumab Biosimilars Market to Hit USD 6044.9 Million by 2033, With 23.4% CAGR
Human Antihistamine Drugs Market Set to Skyrocket, Projected to Exceed USD 706.2 Million by 2033
Editor Details
-
Company:
- Wired Release
- Website:
